Valsartan
Rank #236 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$56.4M
Total Cost
1,481,937
Total Claims
$56.4M
Total Cost
41,149
Prescribers
$38
Cost per Claim
279,682
Beneficiaries
3,608,078
30-Day Fills
$1,370
Avg Cost/Provider
36
Avg Claims/Provider
Share of Medicare Part D Spending
0.02%
of total Medicare Part D spending
$56.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $56.4M total
Top Prescribers of Valsartan
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Xiaoguang Huang | Internal Medicine | Oakland, CA | 1,282 | $57K |
| 2 | Jairo Marin | Interventional Cardiology | Orange, CA | 666 | $42K |
| 3 | Brian Heaster | Internal Medicine | Darlington, SC | 54 | $36K |
| 4 | Alan Blaker | Interventional Cardiology | Florence, SC | 33 | $31K |
| 5 | Kent Chen | Cardiology | Phoenix, AZ | 672 | $30K |
| 6 | Paul Tucker | Interventional Cardiology | Austin, TX | 605 | $29K |
| 7 | Judy Hsu | Internal Medicine | San Francisco, CA | 435 | $29K |
| 8 | Manuel Franco | Internal Medicine | Miami, FL | 833 | $29K |
| 9 | Raymond Raut | Nephrology | Danbury, CT | 634 | $28K |
| 10 | Jorge Robles | Family Practice | El Centro, CA | 645 | $28K |
| 11 | Zoheir Abdelbaki | Cardiology | Lima, OH | 738 | $27K |
| 12 | Rita Goldvug | Internal Medicine | Rego Park, NY | 42 | $27K |
| 13 | Gary Reznik | Cardiology | Los Angeles, CA | 47 | $26K |
| 14 | Sergei Chekov | Internal Medicine | Philadelphia, PA | 833 | $26K |
| 15 | John Cage | Cardiology | Nashville, TN | 481 | $25K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 233 | Everolimus (Everolimus) | $57.0M | 8,962 |
| 234 | Allopurinol (Allopurinol) | $56.9M | 3,852,206 |
| 235 | Exenatide Microspheres (Bydureon Bcise) | $56.6M | 48,670 |
| 236 | Valsartan (Valsartan) | $56.4M | 1,481,937 |
| 237 | Benralizumab (Fasenra Pen) | $54.8M | 9,334 |
| 238 | Netarsudil Mesylat/Latanoprost (Rocklatan) | $54.7M | 103,171 |
| 239 | Amifampridine Phosphate (Firdapse) | $54.4M | 1,203 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology